Outlook Therapeutics grants options and bonuses tied to ONS-5010 BLA progress

Outlook Therapeutics, Inc. disclosed in a Form 8-K that on July 21, 2026, its Compensation Committee approved new stock option grants for its top two executives. Robert C. Jahr, the Company's Chief Executive Officer, was granted 100,000 options and Lawrence A. Kenyon, the Company's Chief Financial Officer, was granted 210,078 options.¹

The options were granted under the company's 2024 Equity Incentive Plan, with an exercise price of $1.4304 per share, matching the Nasdaq Capital Market closing price on the grant date, and they vest on July 21, 2027, contingent on continued service.¹ The company said the awards were granted in recognition of Jahr's and Kenyon's efforts and contributions during 2025 and 2026 in advancing the Biologics License Application for ONS-5010 (bevacizumab-vikg) through the review and appeal processes with the FDA.¹

Separately, the Compensation Committee approved cash bonus opportunities for Jahr and Kenyon of $420,000 and $200,000, respectively.¹ These bonuses carry a strict condition: each will be earned and payable only if the FDA approves ONS-5010 (bevacizumab-vikg) with a favorable BLA decision on or before July 31, 2026.¹

The company said the bonuses reflected Jahr and Kenyon's contributions to advancing the ONS-5010 BLA and the company's non-payment of annual bonuses for their 2025 service.¹ As with the options, any bonus earned will be paid, less applicable deductions and withholdings, subject to the officer's continuing service through the payment date.¹

The filing was signed by Kenyon as Chief Financial Officer and dated July 23, 2026.